MedTrace Logo

Extension Safety and Immunogenicity Study of GPNV-001

NCT05982314 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-18

No results posted yet for this study

Summary

A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.

Conditions

  • Pneumococcal Infections

Interventions

BIOLOGICAL

Gamma-PN3

Experimental whole-cell pneumococcal vaccine

BIOLOGICAL

Pneumovax-23

Licensed pneumococcal vaccine

BIOLOGICAL

Prevenar-13

Licensed pneumococcal vaccine

BIOLOGICAL

Placebo

Saline placebo

Sponsors & Collaborators

  • GPN Vaccines

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-17
Primary Completion
2024-08-30
Completion
2024-08-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05982314 on ClinicalTrials.gov